TY - JOUR
T1 - Use of brodalumab for the treatment of chronic plaque psoriasis
T2 - a one-year real-life study in the Lazio region, Italy
AU - Galluzzo, M
AU - Caldarola, G
AU - De Simone, C
AU - Bernardini, N
AU - Moretta, G
AU - Pallotta, S
AU - Botti, E
AU - Campione, E
AU - Pirro, F
AU - Potenza, C
AU - Bianchi, L
AU - Peris, K
PY - 2021/9
Y1 - 2021/9
N2 - Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.
AB - Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression.Results: After 48 weeks, 92.2% of patients (mean age 50.2 ± 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 ± 10.3 at baseline to 1.7 ± 3.9 and 1.4 ± 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks.Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission.Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.
KW - Adult
KW - Aged
KW - Antibodies, Monoclonal, Humanized
KW - Humans
KW - Middle Aged
KW - Psoriasis/drug therapy
KW - Retrospective Studies
KW - Severity of Illness Index
KW - Treatment Outcome
U2 - 10.1080/14712598.2021.1941862
DO - 10.1080/14712598.2021.1941862
M3 - Article
C2 - 34114515
SN - 1471-2598
VL - 21
SP - 1299
EP - 1310
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
IS - 9
ER -